stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) Return on invested capital
Penumbra, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 12.7%, down 0.4 percentage points from fiscal 2025 (13.1%). Over the past ten years it has ranged from −6.08% (fiscal 2020) to 13.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −5.27% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 13.1% | 12.39 |
| FY2024 | 0.70% | (4.33) |
| FY2023 | 5.03% | 4.58 |
| FY2022 | 0.45% | 1.10 |
| FY2021 | −0.65% | 5.43 |
| FY2020 | −6.08% | (15.27) |
| FY2019 | 9.19% | 9.43 |
| FY2018 | −0.24% | (0.63) |
| FY2017 | 0.39% | 1.00 |
| FY2016 | −0.61% | (3.73) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PODD Insulet Corporation compare | 18.8% |
| PEN Penumbra, Inc. | 12.7% |
| GMED Globus Medical, Inc. compare | 8.86% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BIO.B Bio-Rad Laboratories, Inc. compare | −0.44% |
| BIO Bio-Rad Laboratories, Inc. compare | −0.44% |
| BRKR Bruker Corporation compare | −1.12% |
| TXG 10x Genomics compare | −20.2% |
| GKOS Glaukos Corporation compare | −24.6% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on PEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement